Latest Information Update: 12 Jun 2000
At a glance
- Originator Merck & Co
- Developer Takeda
- Class Antiasthmatics
- Mechanism of Action Platelet activating factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 12 Jun 2000 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 29 Mar 1996 Preclinical development for Thrombosis in Japan (Unknown route)